|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.031 AUD | +6.90% |
|
+10.71% | +29.17% |
| Apr. 08 | AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market | MT |
| Feb. 26 | AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
AdAlta Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported sales was AUD 1.14 million compared to AUD 1.11 million a year ago. Net loss was AUD 3.01 million compared to AUD 2.82 million a year ago.
Basic loss per share from continuing operations was AUD 0.0066 compared to AUD 0.009 a year ago. Diluted loss per share from continuing operations was AUD 0.0066 compared to AUD 0.009 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.17% | 10.63M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ADALTA LIMITED 
